Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Trial Profile

A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Preeclampsia; Radiation injuries
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has granted permission to start this Phase I trial.
    • 01 Nov 2018 According to an A1M Pharma AB media release, this trial is expected to begin in the first quarter of 2019.This study is estimated to take approximately six months to complete.
    • 20 Sep 2018 According to an A1M Pharma AB media release, a new application has been submitted to the Swedish Medicines Agency , and data from the new production has been included in a renewed application. This study will be conducted together with the contract research company CTC in Uppsala.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top